Delcath Systems Inc (DCTH)vsMerck & Company Inc (MRK)
DCTH
Delcath Systems Inc
$13.01
-3.77%
HEALTHCARE · Cap: $446.71M
MRK
Merck & Company Inc
$123.54
-1.22%
HEALTHCARE · Cap: $308.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 72619% more annual revenue ($65.77B vs $90.44M). MRK leads profitability with a 13.6% profit margin vs 0.6%. DCTH appears more attractively valued with a PEG of 1.60. MRK earns a higher WallStSmart Score of 50/100 (D+).
DCTH
Hold35
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCTH.
Margin of Safety
-52.6%
Fair Value
$80.96
Current Price
$123.54
$42.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 26.3% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.5% — below average capital efficiency
0.6% margin — thin
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 1294.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
DCTH profiles as a growth stock while MRK is a value play — different risk/reward profiles.
DCTH carries more volatility with a beta of 0.52 — expect wider price swings.
DCTH is growing revenue faster at 26.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?